Please assess the completion status of the following clinical trial:

Trial Title: Study of Adalimumab Treatment for Induction and Maintenance of Clinical Remission in Subjects With Crohn's Disease

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of moderate to severe Crohn's Disease confirmed by endoscopy or radiologic evaluation for greater than 4 months (16 weeks)~* Inadequate response to conventional therapy for Crohn's Disease~* Subjects \>=18 and \<=75 years of age and in good health (Investigator discretion) with a recent stable medical history~* Harvey Bradshaw Index score of 7 or higher~Exclusion Criteria:~* Subject considered by the investigator, for any reason, to be an unsuitable candidate for the study~* Subject who has had surgical bowel resections within the past 6 months or is planning any resection at any time point while enrolled in the study~* Female subject who is pregnant or breast-feeding or considering becoming pregnant~* Previous treatment with adalimumab or previous participation in an adalimumab clinical study~* Subject considered by the investigator, for any reason, to be an unsuitable candidate for the study~* Subjects with any prior exposure to Tysabri® (natalizumab)~* Subjects on prednisone \>40 mg/day (or equivalent), subjects on budesonide \>9 mg/day, or subjects who are taking prednisone and budesonide concurrently at Baseline

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Open Label (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).